The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
Background Fabry disease (FD) causes multiorgan sphingolipid accumulation, with cardiac involvement responsible for the ...
In this retrospective cohort study, decline in kidney function was frequent in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and was consistently associated with an increased risk of ...
Transforming Perspectives on Transthyretin Amyloid Cardiomyopathy ... be sure to join us for a highly anticipated oral presentation on “Echocardiography in Hypertrophic Cardiomyopathy: Virtual CME ...
Medpage Today on MSN16d
Inching Toward a Blood Test for Hypertrophic CardiomyopathyA small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH), researchers found. From ...
Introduction: Hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA) have similar features on transthoracic echocardiography (TTE) which may make the two difficult to distinguish. However, it ...
Background Variant transthyretin amyloidosis (ATTRv) is a hereditary multisystem disorder with clinical spectrum ranging from predominant cardiomyopathy to polyneuropathy ... Transthoracic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback